Document Detail

What Do We Do with Chronic Lymphocytic Leukemia with 17p Deletion?
MedLine Citation:
PMID:  23188619     Owner:  NLM     Status:  Publisher    
Chronic lymphocytic leukemia (CLL) with 17p deletion or mutations of the TP53 gene has a very poor outcome. Optimal treatment of these patients remains a major clinical challenge, and disagreement on the optimal treatment approach exists. Conventional chemo-immunotherapy with rituximab in combination with purine analogues yields lower response-rates and less satisfactory results than for CLL patients with intact p53. Allogeneic stem cell transplantation may allow long-term remissions in this challenging group of patients. In this review, we will discuss current treatment options as well as experimental approaches in clinical trials for CLL patients with deleted or mutated TP53. Particular emphasis will be placed on novel agents with the potential to change clinical practice and future perspectives for the management of these "highest risk" patients.
L Sellner; S Denzinger; S Dietrich; H Glimm; O Merkel; P Dreger; T Zenz
Related Documents :
20184709 - Mass barium carbonate poisoning with fatal outcome, lessons learned: a case series.
16798589 - Applying physiology to conventional mechanical ventilation.
24762219 - Trichodysplasia spinulosa: rare presentation of polyomavirus infection in immunocomprom...
23188619 - What do we do with chronic lymphocytic leukemia with 17p deletion?
365289 - Physiotherapy and intermittent positive-pressure ventilation of chronic bronchitis.
7356209 - The esophageal obturator airway: a study of respiratory effectiveness.
8759669 - The safety and efficacy of percutaneous endoscopic gastrostomy after recent myocardial ...
6490319 - The significance of focal segmental glomerulosclerosis in oligomeganephronia.
8431139 - Profiles of language impairment in primary progressive aphasia.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-28
Journal Detail:
Title:  Current hematologic malignancy reports     Volume:  -     ISSN:  1558-822X     ISO Abbreviation:  Curr Hematol Malig Rep     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101262565     Medline TA:  Curr Hematol Malig Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rectal cancer: Assessment of response to neoadjuvant chemoradiation by dynamic contrast-enhanced MRI...
Next Document:  Pilot survey on dental health in 5-12-year-old school children in Laos.